ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 168 filers reported holding ESPERION THERAPEUTICS INC NE in Q2 2019. The put-call ratio across all filers is 1.06 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $294 | -29.5% | 300 | 0.0% | 0.00% | – |
| Q2 2023 | $417 | -12.6% | 300 | 0.0% | 0.00% | – |
| Q1 2023 | $477 | -74.5% | 300 | 0.0% | 0.00% | – |
| Q4 2022 | $1,869 | -6.6% | 300 | 0.0% | 0.00% | – |
| Q3 2022 | $2,000 | 0.0% | 300 | 0.0% | 0.00% | – |
| Q2 2022 | $2,000 | 0.0% | 300 | 0.0% | 0.00% | – |
| Q4 2021 | $2,000 | -66.7% | 300 | 0.0% | 0.00% | – |
| Q2 2021 | $6,000 | -25.0% | 300 | 0.0% | 0.00% | -100.0% |
| Q1 2021 | $8,000 | 0.0% | 300 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $8,000 | -27.3% | 300 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $11,000 | -26.7% | 300 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $15,000 | +66.7% | 300 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $9,000 | -50.0% | 300 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $18,000 | +63.6% | 300 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $11,000 | -21.4% | 300 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $14,000 | +16.7% | 300 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $12,000 | -14.3% | 300 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $14,000 | +7.7% | 300 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $13,000 | +8.3% | 300 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $12,000 | -45.5% | 300 | 0.0% | 0.00% | -50.0% |
| Q1 2018 | $22,000 | +10.0% | 300 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $20,000 | +33.3% | 300 | 0.0% | 0.00% | +100.0% |
| Q3 2017 | $15,000 | +7.1% | 300 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $14,000 | +27.3% | 300 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $11,000 | +175.0% | 300 | 0.0% | 0.00% | – |
| Q4 2016 | $4,000 | 0.0% | 300 | 0.0% | 0.00% | -100.0% |
| Q3 2016 | $4,000 | +33.3% | 300 | 0.0% | 0.00% | – |
| Q2 2016 | $3,000 | -40.0% | 300 | 0.0% | 0.00% | -100.0% |
| Q1 2016 | $5,000 | -28.6% | 300 | 0.0% | 0.00% | 0.0% |
| Q4 2015 | $7,000 | +75.0% | 300 | +100.0% | 0.00% | 0.0% |
| Q3 2015 | $4,000 | -50.0% | 150 | +50.0% | 0.00% | 0.0% |
| Q2 2015 | $8,000 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $22,344,000 | 10.09% |
| Altium Capital Management LP | 2,515,785 | $12,579,000 | 3.47% |
| Deep Track Capital, LP | 5,641,668 | $28,208,000 | 1.99% |
| Paradigm Biocapital Advisors LP | 839,257 | $4,196,000 | 1.20% |
| SABBY MANAGEMENT, LLC | 940,400 | $4,702,000 | 0.68% |
| Monaco Asset Management SAM | 500,000 | $2,500,000 | 0.62% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 5,000,000 | $25,000,000 | 0.52% |
| CVI Holdings, LLC | 1,460,595 | $7,303,000 | 0.48% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $13,566,000 | 0.38% |
| Rhenman & Partners Asset Management AB | 1,000,000 | $4,960,000 | 0.33% |